UBS keeps Eli Lilly at Buy and lifts target to $1625
UBS maintained its Buy rating on Eli Lilly and raised its price target to $1625 a share from $1425, according to Dow Jones Newswires.
- published on Newsmetry
- original source published
the same feed is available to bots and dashboards through the api. connect the api →
what happened
UBS kept its Buy rating on Eli Lilly shares and raised the stock's price target to $1625 a share from $1425. The information was published by Dow Jones Newswires, citing ratings data from Benzinga.
The report covers a single analyst rating action and includes no new financial figures from the company.
why it matters
Analyst decisions like this can shape sentiment around the stock, but they usually have limited impact on the broader market.
tags
instruments
sources
- Eli Lilly Is Maintained at Buy by UBS — Dow Jones Newswires, 31 October 2026 at 02:19 UTC
prepared by the newsmetry newsroom with ai assistance from the sources listed below. not investment advice.
alerts on your topics, the morning digest and the api — in your account.
get stories in real time ↗